Gamifant

Active Ingredient(s): Emapalumab-lzsg
FDA Approved: * November 20, 2018
Pharm Company: * NOVIMMUNE S.A.
Category: Genetic Disorders

Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH),[3][4][5] which has no cure.[6] The most common side effects include infections, hypertension, infusion-related reactions, and pyrexia.[3] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7&a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Gamifant 10 mg/2ml Intravenous Injection
NDC: 66658-501
Labeler:
Swedish Orphan Biovitrum Ab (Publ)
Gamifant 50 mg/10ml Intravenous Injection
NDC: 66658-505
Labeler:
Swedish Orphan Biovitrum Ab (Publ)
Gamifant 100 mg/20ml Intravenous Injection
NDC: 66658-510
Labeler:
Swedish Orphan Biovitrum Ab (Publ)
Gamifant 10 mg/2ml Intravenous Injection
NDC: 72171-501
Labeler:
Novimmune Sa
Gamifant 50 mg/10ml Intravenous Injection
NDC: 72171-505
Labeler:
Novimmune Sa